Evidence map›Paper›PMID 29434471›Full record

ArticleBreast cancer : basic and clinical research2017

Prognostic Significance of Low Claudin3 Expression in Luminal Breast Cancers.

Lakmini Mudduwa, Harshini Peiris, Shania Gunasekara, Deepthika Abeysiriwardhana, Thusharie Liyanage

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer : basic and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Lakmini MudduwaDepartment of Pathology, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.
Harshini PeirisMedical Laboratory Science Degree Programme, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.
Shania GunasekaraDepartment of Pathology, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.
Deepthika AbeysiriwardhanaDepartment of Pathology, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.
Thusharie LiyanageDepartment of Pathology, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.
University of Ruhuna · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo study the prognostic value of immunohistochemically detected low Claudin3 expression in breast cancers.

methodsThis retrospective study included patients with breast cancer who were investigated at our unit from 2006 to 2015. Tissue microarrays were constructed, and immunohistochemical staining was done to assess the Claudin3 expression and to classify breast cancers according to the immunohistochemical surrogates for molecular classification. Kaplan-Meier model and log-rank test were used for recurrence-free survival and breast cancer-specific survival analysis.

resultsOf the 853 patients, overall low expression of Claudin3 was seen in 18.4%. Recurrence-free survival of patients with overall low Claudin3 breast cancers was poor in luminal A (

conclusionsAssessment of Claudin3 expression by immunohistochemistry is suggested for luminal A and luminal B (Her2-) subtypes to identify patients with poor prognosis.

Indexed as

breast cancer survivalClaudin3 expressionmolecular classification

Identifiers

PMID29434471
PMCPMC5802694
OpenAlexW2771931623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.